Key result
Spironolactone decreased cell volume and downregulated ANP and BNP protein expression in isoproterenol-induced cardiomyocyte hypertrophy.
Why the study?
The study aimed to investigate the protective effect and molecular mechanism of spironolactone in isoproterenol-induced cardiomyocyte hypertrophy.
Does spironolactone prevent isoproterenol-induced cardiomyocyte hypertrophy in neonatal rat cardiomyocytes?
Does spironolactone prevent isoproterenol-induced cardiomyocyte hypertrophy in neonatal rat cardiomyocytes?
Spironolactone reverses isoproterenol-induced cardiomyocyte hypertrophy by inhibiting the Ca2+/CaN/NFATc3 pathway in a preclinical model.
Answers are grounded in this paper and cite their sources.
Does not support clinical use in hypertrophy; leaves open translation of rat in vitro findings to humans.
This study aimed to investigate the protective effect and molecular mechanism of spironolactone in isoproterenol-induced cardiomyocyte hypertrophy. In this study, primary cardiomyocytes were extracted from the heart of neonatal rats. After stable culture, they were processed with isoproterenol alone or isoproterenol (10 μM) combined with different doses (low dose of 10 μM and high dose of 50 μM), and the cellular activity was determined by MTT experiment. The volume of cells was measured with an inverted microscope and CIAS-1000 cell image analysis system. The mRNA expression levels of ANP and BNP in cells were explored by RT-qPCR. The levels of ANP and BNP proteins and NFATc3 phosphorylation in the nucleus were detected by western blot. The extracellular Ca2+ concentration and CaN activity were measured by colorimetry with the kit. Isoproterenol significantly enlarged the volume of cardiomyocytes ( <a:math xmlns:a="http://www.w3.org/1998/Math/MathML" id="M1"> <a:mi>p</a:mi> <a:mo><</a:mo> <a:mn>0.001</a:mn> </a:math> ), upregulated mRNA and expression levels of ANP and BNP proteins ( <c:math xmlns:c="http://www.w3.org/1998/Math/MathML" id="M2"> <c:mi>p</c:mi> <c:mo><</c:mo> <c:mn>0.001</c:mn> </c:math> ), increased extracellular Ca2+ concentration and CaN activity ( <e:math xmlns:e="http://www.w3.org/1998/Math/MathML" id="M3"> <e:mi>p</e:mi> <e:mo><</e:mo> <e:mn>0.001</e:mn> </e:math> ), and upregulated NFATc3 phosphorylation in the nucleus ( <g:math xmlns:g="http://www.w3.org/1998/Math/MathML" id="M4"> <g:mi>p</g:mi> <g:mo><</g:mo> <g:mn>0.001</g:mn> </g:math> ). The volume of cells treated with isoproterenol combined with different doses of spironolactone significantly decreased compared with those treated with isoproterenol alone ( <i:math xmlns:i="http://www.w3.org/1998/Math/MathML" id="M5"> <i:mi>p</i:mi> <i:mo><</i:mo> <i:mn>0.001</i:mn> </i:math> ). mRNA and expression levels of ANP and BNP proteins downregulated significantly ( <k:math xmlns:k="http://www.w3.org/1998/Math/MathML" id="M6"> <k:mi>p</k:mi> <k:mo><</k:mo> <k:mn>0.001</k:mn> </k:math> ). The extracellular Ca2+ ( <m:math xmlns:m="http://www.w3.org/1998/Math/MathML" id="M7"> <m:mi>p</m:mi> <m:mo><</m:mo> <m:mn>0.01</m:mn> </m:math> ) concentration and CaN activity ( <o:math xmlns:o="http://www.w3.org/1998/Math/MathML" id="M8"> <o:mi>p</o:mi> <o:mo><</o:mo> <o:mn>0.001</o:mn> </o:math> ) decreased significantly, and NFATc3 phosphorylation in the nucleus downregulated significantly ( <q:math xmlns:q="http://www.w3.org/1998/Math/MathML" id="M9"> <q:mi>p</q:mi> <q:mo><</q:mo> <q:mn>0.001</q:mn> </q:math> ). There was no significant difference in cell volume ( <s:math xmlns:s="http://www.w3.org/1998/Math/MathML" id="M10"> <s:mi>p</s:mi> <s:mo>=</s:mo> <s:mn>0.999</s:mn> </s:math> ), ANP and BNP mRNA ( <u:math xmlns:u="http://www.w3.org/1998/Math/MathML" id="M11"> <u:mi>p</u:mi> <u:mo>=</u:mo> <u:mn>0.695</u:mn> </u:math> ), expression levels of proteins, CaN activity (0.154), and NFATc3 phosphorylation in the nucleus between the cells treated with isoproterenol combined with high-dose spironolactone and those in the control group. In conclusion, spironolactone can reverse isoproterenol-induced cardiomyocyte hypertrophy by inhibiting the Ca2+/CaN/NFATc3 pathway.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) studied Isoproterenol-induced cardiomyocyte hypertrophy. Spironolactone vs. Isoproterenol alone was evaluated on Cardiomyocyte volume and expression levels of ANP, BNP, and NFATc3 phosphorylation (p=<0.001). Spironolactone decreased cell volume and downregulated ANP and BNP protein expression in isoproterenol-induced cardiomyocyte hypertrophy.
Synapse has enriched 10 related papers. Consider them for comparative context: